Summary
Atezolizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cervical Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cervical Cancer. ClinicalTrials.gov lists 8 registered trials linking Atezolizumab to Cervical Cancer: 2 are currently recruiting; 1 is active or not yet recruiting; 3 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT06422403). It plans or enrolled 360 participants. Registration activity spans 2017 to 2024. The literature layer holds 11 publications for this pair: 3 Cochrane reviews, 1 meta-analysis, 2 randomised controlled trial publications and 5 clinical trial publications. Publication years run from 2021 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Cervical Cancer ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: CIN2/3 (precancerous): spontaneous regression in 40-60% of CIN2 without treatment; CIN3: regression in ~30%; invasive cervical cancer: no spontaneous regression.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 73.0 (trials 23.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 2 recruiting, 1 active / not yet recruiting, 3 completed, 2 other |
| Linked publications | 11 (5 clinical trial publications, 3 Cochrane reviews, 2 randomised controlled trial publications, 1 meta-analysis) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | antibody; immunotherapy |
| Data sources | DGIdb |
| Linked via biomarker / target | ARID1A |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT03181100 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer 2017 | active, not recruiting | Phase 2 | 50 |
| NCT04939480 | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN 2021 | completed | Phase 2 | 20 |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers 2024 | recruiting | Phase 2 | 360 |
| NCT06254911 | Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma 2023 | suspended | Phase 2 | 20 |
| NCT02914470 | Carboplatin-cyclophosphamide Combined With Atezolizumab 2017 | completed | Phase 1 | 12 |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors 2019 | completed | Phase 1 | 37 |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors 2022 | terminated | Phase 1 | 5 |
| NCT04954599 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI 2023 | recruiting | PHASE1, PHASE2 | 126 |
Published literature
- Clinical trial publication Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancerKim H, Deng W, Zamarin D et al. · Brachytherapy · 2026 · PMID 41107078
- Clinical trial publication Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional StudyAhmed KA, Quick AM, Chon HS et al. · International journal of radiation oncology, biology, physics · 2026 · PMID 40379142
- Cochrane review Efficacy and safety of immune checkpoint inhibitors combined with chemoradiotherapy in locally advanced cervical cancer: a systematic review and meta-analysisXiao C, Zeng S, Li L et al. · Frontiers in pharmacology · 2026 · PMID 41859340
- Cochrane review Immune checkpoint therapy in locally advanced, persistent, recurrent, and metastatic cervical cancer: A systematic review and Bayesian network meta-analysisHinojosa-Gonzalez DE, Escarcega-Bordagaray JA, Murillo-Torres RM et al. · International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026 · PMID 41239828
- Meta-analysis Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapyWang X, Zhang Y, Wang C et al. · Frontiers in immunology · 2026 · PMID 42079658
- Clinical trial publication Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATccTakekuma M, Nishio S, Yamaguchi S et al. · Journal of gynecologic oncology · 2025 · PMID 40968753
- Clinical trial publication Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trialMayadev J, Zamarin D, Deng W et al. · Nature communications · 2025 · PMID 39788967
- Clinical trial publication Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a studyHillemanns P, Zikan M, Forget F et al. · Journal for immunotherapy of cancer · 2025 · PMID 39773564
- Randomized controlled trial A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)Salani R, McCormack M, Kim YM et al. · International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024 · PMID 38858106
- Randomized controlled trial Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialOaknin A, Gladieff L, Martínez-García J et al. · Lancet (London, England) · 2024 · PMID 38048793
- Cochrane review Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-AnalysisJiang L, Tan X, Li J et al. · Frontiers in oncology · 2021 · PMID 34712609
Mechanism and notes
Recorded mechanism or class: antibody; immunotherapy.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ARID1A. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Atezolizumab approved for Cervical Cancer?
Atezolizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cervical Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cervical Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Atezolizumab in clinical trials for Cervical Cancer?
ClinicalTrials.gov lists 8 registered trials linking Atezolizumab to Cervical Cancer: 2 are currently recruiting; 1 is active or not yet recruiting; 3 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT06422403). It plans or enrolled 360 participants. Registration activity spans 2017 to 2024.
What does the evidence show for Atezolizumab in Cervical Cancer?
Atezolizumab has both completed registered trials and synthesis-level publications linked to Cervical Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ARID1A. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.